News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech IPO Slump Continues as Alder Biopharmaceuticals Inc. Prices Below Range


5/8/2014 8:50:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

As Alder Biopharmaceuticals can attest to today, the biotech IPO train has hit the skids. The Bothell, WA-based company has priced its IPO at $10 per share, well below its projected $13 to $15 per share range, according to IPO research firm Renaissance Capital. Alder upsized its offering to 8 million shares from 7.2 million to take itself public, good for an $80 million haul before discounts due to underwriters—but far short of the $115 million it planned to raise when it first filed its S-1 in March. Alder will begin trading today on the Nasdaq today under the ticker symbol “ALDR.”

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy

comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES